Urinoma - 29/10/21
Doi : 10.1016/j.ajog.2021.06.049
Plan
| All authors and committee members have filed a conflict of interest disclosure delineating personal, professional, business, or other relevant financial or nonfinancial interests in relation to this publication. Any substantial conflicts have been addressed through a process approved by the Society for Maternal-Fetal Medicine (SMFM) Board of Directors. Moreover, the SMFM has neither solicited nor accepted any commercial involvement in the specific content development of this publication. |
|
| This document has undergone an internal peer review through a multilevel committee process within the SMFM. The review involved critique and feedback from the SMFM Publications and Document Review Committees and final approval by the SMFM Executive Committee. SMFM accepts sole responsibility for the document content. SMFM publications do not undergo editorial and peer review by the American Journal of Obstetrics & Gynecology. The SMFM Publications Committee reviews publications every 18 to 24 months and issues updates as needed. Further details regarding SMFM publications can be found at publications. |
|
| SMFM recognizes that obstetric patients have diverse gender identities and is striving to use gender-inclusive language in all of its publications. SMFM will be using the terms “pregnant person or persons” or “pregnant individual or individuals” instead of “pregnant woman or women” and will use the singular pronoun “they.” When describing study populations used in research, SMFM will use the gender terminology reported by the study investigators. |
|
| All questions or comments regarding the document should be referred to the SMFM Publications Committee at pubs@smfm.org. |
|
| Reprints will not be available. |
© 2021
Publié par Elsevier Masson SAS.
Vol 225 - N° 5
P. B34-B35 - novembre 2021 Retour au numéro
Article précédent
- Renal agenesis
- Society for Maternal-Fetal Medicine (SMFM), Angie Jelin
- Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery : Replaces SMFM Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016
- Society for Maternal-Fetal Medicine (SMFM), Uma M. Reddy, Uma Deshmukh, Annie Dude, Lorie Harper, Sarah S. Osmundson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?